187 related articles for article (PubMed ID: 8414502)
1. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
3. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
4. p53 transactivation through various p53-responsive elements.
Park DJ; Chumakov AM; Miller CW; Pham EY; Koeffler HP
Mol Carcinog; 1996 Jun; 16(2):101-8. PubMed ID: 8645424
[TBL] [Abstract][Full Text] [Related]
5. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
6. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
7. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
[TBL] [Abstract][Full Text] [Related]
8. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
Shivakumar CV; Das GC
Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
[TBL] [Abstract][Full Text] [Related]
9. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
[TBL] [Abstract][Full Text] [Related]
10. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
11. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
Tarunina M; Jenkins JR
Oncogene; 1993 Nov; 8(11):3165-73. PubMed ID: 8414520
[TBL] [Abstract][Full Text] [Related]
12. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
13. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
14. Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site.
Suzuki T; Uchida-Toita M; Yoshida M
Oncogene; 1999 Jul; 18(28):4137-43. PubMed ID: 10435595
[TBL] [Abstract][Full Text] [Related]
15. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif.
Ragimov N; Krauskopf A; Navot N; Rotter V; Oren M; Aloni Y
Oncogene; 1993 May; 8(5):1183-93. PubMed ID: 8479742
[TBL] [Abstract][Full Text] [Related]
16. Steroidogenic factor 1-dependent promoter activity of the human steroidogenic acute regulatory protein (StAR) gene.
Sugawara T; Holt JA; Kiriakidou M; Strauss JF
Biochemistry; 1996 Jul; 35(28):9052-9. PubMed ID: 8703908
[TBL] [Abstract][Full Text] [Related]
17. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
[TBL] [Abstract][Full Text] [Related]
18. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
Kichina JV; Rauth S; Das Gupta TK; Gudkov AV
Oncogene; 2003 Jul; 22(31):4911-7. PubMed ID: 12894234
[TBL] [Abstract][Full Text] [Related]
19. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions.
Subler MA; Martin DW; Deb S
Oncogene; 1994 May; 9(5):1351-9. PubMed ID: 8152795
[TBL] [Abstract][Full Text] [Related]
20. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
